Researcher:
Somay, Kayra

Profile Picture
ORCID

Job Title

Researcher

First Name

Kayra

Last Name

Somay

Name

Name Variants

Somay, Kayra

Email Address

Birth Date

Filters

2020 - 20225

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.26c68220-4697-4057-9c3a-b4c19b17d04c

Search Results

Now showing 1 - 5 of 5
  • Placeholder
    PublicationMetadata only
    Immature platelet fraction: Is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?
    (De Gruyter Open Ltd, 2021) Tasdemir, Z.A.; Palaoğlu, K.E.; N/A; İncir, Said; Komesli, Zeynep; Baygül, Arzu Eden; Çaltı, Hatice Kant; Kapmaz, Mahir; Tekin, Süda; Kılıç, Alparslan; Dağel, Tuncay; Okan, Ayşe; Somay, Kayra; Akpınar, Timur Selçuk; Doctor; Doctor; Faculty Member; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Doctor; Faculty Member; N/A; N/A; School of Medicine; N/A; N/A; N/A; N/A; N/A; N/A; N/A; School of Medicine; Koç University Hospital; Koç University Hospital; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; Koç University Hospital; Koç University Hospital; Koç University Hospital; Koç University Hospital; N/A; 175430; N/A; 272290; N/A; N/A; 42146; N/A; N/A; N/A; N/A; 216646
    Objectives : In many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome. This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19). Methods : A total of 154 patients with COVID‐19 infections were included. The patients were divided into two groups according to the severity of pneumonia (severe and non-severe) regarding their oxygen demand. Results : Given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p<0.001). Mean platelet volume (p<0.001), platelet-large cell ratio (p=0.001), platelet distribution width (p=0.001), D-Dimer (p<0.001), INR (p=0.003), and aPTT (p=0.007) were also found to be significantly higher in the severe group. Moreover, IPF (p=0.014, Odds ratio = 2.000, 95%CI: 1.149-3.482) was an independent predictor for the severity. The curve value from receiver operating characteristics was 0.879 (p<0.001, 95%CI: 0.784-0.943) for determining the severity of pneumonia. IPF% had a sensitivity and specificity value of 69.5 and 92.4% to detect the disease’s severity. Conclusions : IPF% is an independent predictor for the severity of COVID-19 pneumonia. Assessment of IPF% may both help to early determine high-risk patients with COVID-19 and to alert the physicians. / Amaç : Pek çok hastalıkta, immatür platelet fraksiyonu (%İPF), koagülopati ve kötü sonuçla ilişkilidir. Bu çalışma, Coronavirus Hastalığı 2019 (COVID-19) olan hastalarda pnömoni şiddeti için %İPF’nin prediktif değerini araştırmayı amaçladı. Yöntem : COVID-19 enfeksiyonu olan toplam 154 hasta dahil edildi. Hastalar, oksijen ihtiyaçları göz önüne alınarak pnömoni şiddetine göre (ağır ve ağır olmayan) iki gruba ayrıldı. Bulgular : Laboratuvar parametrelerine bakıldığında, medyan İPF yüzdesi ağır grupta anlamlı olarak daha yüksekti (%11.9′a karşı %3.9, p<0.001). Ortalama trombosit hacmi (p<0.001), trombosit-büyük hücre oranı (p=0.001), trombosit dağılım genişliği (p=0.001), D-Dimer (p<0.001), İNR (p=0.003) ve aPTT (p=0.007) ağır grupta anlamlı olarak daha yüksek bulundu. Ayrıca, İPF (p=0.014, Odds oranı = 2.000, %95 CI: 1.149-3.482) hastalık şiddeti için bağımsız bir öngördürücü olarak bulundu. Algılayıcı işletim eğrisinden gelen eğri değeri, pnömoni şiddetini belirlemek için 0.879 (p<0.001, %95 CI: 0.784-0.943) idi. İPF, hastalığın şiddetini saptamak için %69.5′lik duyarlılık ve %92.4′lük özgüllük değerine sahipti. Sonuç : İPF, COVID-19 pnömonisinin şiddeti için bağımsız bir öngörücüdür. %İPF’nin değerlendirilmesi, hem COVID-19′lu yüksek riskli hastaları erken belirlemeye hem de hekimleri uyarmaya yardımcı olabilir.
  • Placeholder
    PublicationMetadata only
    An unusual case of extrapulmonary tuberculosis in rheumatology consultation
    (Aves, 2022) Somay, Kayra; Eren, İlker; Kapmaz, Mahir; Çağlayan, Benan Niku; Karakaya, Afak Durur; Kanıtez, Nilüfer Alpay; Researcher; Faculty Member; Doctor; Faculty Member; Faculty Member; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; 168021; N/A; 230719; 269567; 239432
    N/A
  • Thumbnail Image
    PublicationOpen Access
    Hiv-associated non hodgkin lymphoma: a case series study from Turkey
    (African Traditional Herbal Medicine Supporters Initiative, 2020) Somay, Kayra; Çöpür, Sidar; Osmanbaşoğlu, Emre; Masyan, Helin; Arslan, Harun; Akay, Olga Meltem; Tekin, Süda; Ferhanoğlu, Ahmet Burhan; Researcher; Faculty Member; Faculty Member; School of Medicine; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; N/A; N/A; 18320
    Background: human immunodeficiency virus (HIV) is a global health concern with major risks for opportunistic infections and predisposition to malignancies including Kaposi sarcoma associated with Human Herpes Virus-8 (HHV-8) and non-Hodgkin lymphoma (NHL) commonly associated with Epstein Barr Virus (EBV). Although the exact mechanisms of predisposition to certain malignancies are unclear, HIV (+) cancer patients typically have poorer prognosis. Materials and methods: we included all five HIV positive NHL patients receiving antiretroviral therapy (ART) and chemotherapy in our clinic and aim to determine their follow-up outcomes associated with ART. Results: the use of ART in conjunction with chemotherapy regimens lead to better therapeutic outcome in our cases with no mortality over three years of follow-up despite high rates of poor prognostic factors and studies demonstrating 1-year survival rates of approximately 30% in HIV-associated lymphoma. No significant adverse effect has been recorded. Conclusion: we recommend use of ART along with chemotherapy regimens in HIV positive lymphoma patients for better treatment response.
  • Thumbnail Image
    PublicationOpen Access
    Immature platelet fraction: is a novel early predictive marker for disease severity in patients with Covid-19 pneumonia?
    (De Gruyter, 2021) Taşdemir, Zeynep Atam; Paloğlu, Kerim Erhan; İncir, Said; Komesli, Zeynep; Baygül, Arzu Eden; Çaltı, Hatice Kant; Kapmaz, Mahir; Tekin, Süda; Kılıç, Alparslan; Dağel, Tuncay; Okan, Ayşe; Somay, Kayra; Akpınar, Timur Selçuk; Faculty Member; Doctor; Doctor; Faculty Member; School of Medicine; Koç University Hospital; N/A; N/A; 272290; N/A; N/A; 42146; N/A; N/A; N/A; N/A; N/A
    Objectives: in many diseases, immature platelet fraction (IPF%) is related to coagulopathy and poor outcome. This study aimed to investigate the predictive value of IPF% for the severity of pneumonia in patients with Coronavirus Disease 2019 (COVID-19). Methods: a total of 154 patients with COVID-19 infections were included. The patients were divided into two groups according to the severity of pneumonia (severe and nonsevere) regarding their oxygen demand. Results: given laboratory parameters, the median IPF% was significantly higher in the severe group (11.9 vs. 3.9%, p<0.001). Mean platelet volume (p<0.001), platelet-large cell ratio (p=0.001), platelet distribution width (p=0.001), D-Dimer (p<0.001), INR (p=0.003), and aPTT (p=0.007) were also found to be significantly higher in the severe group. Moreover, IPF (p=0.014, Odds ratio = 2.000, 95%CI: 1.149-3.482) was an independent predictor for the severity. The curve value from receiver operating characteristics was 0.879 (p<0.001, 95%CI: 0.784-0.943) for determining the severity of pneumonia. IPF% had a sensitivity and specificity value of 69.5 and 92.4% to detect the disease's severity. Conclusions: IPF% is an independent predictor for the severity of COVID-19 pneumonia. Assessment of IPF% may both help to early determine high-risk patients with COVID-19 and to alert the physicians. / Amaç: pek çok hastalıkta, immatür platelet fraksiyonu (%İPF), koagülopati ve kötü sonuçla ilişkilidir. Bu çalışma, Coronavirus Hastalığı 2019 (COVID-19) olan hastalarda pnömoni şiddeti için %İPF’nin prediktif değerini araştırmayı amaçladı. Yöntem: COVID-19 enfeksiyonu olan toplam 154 hasta dahil edildi. Hastalar, oksijen ihtiyaçları göz önüne alınarak pnömoni şiddetine göre (ağır ve ağır olmayan) iki gruba ayrıldı. Bulgular: laboratuvar parametrelerine bakıldığında, medyan İPF yüzdesi ağır grupta anlamlı olarak daha yüksekti (% 11.9?a karşı %3.9, p<0.001). Ortalama trombosit hacmi (p<0.001), trombosit-büyük hücre oranı (p=0.001), trombosit dağılım genişliği (p=0.001), D-Dimer (p<0.001),İNR (p=0.003) ve aPTT (p=0.007) ağır grupta anlamlı olarak daha yüksek bulundu. Ayrıca, İPF (p=0.014, Odds oranı = 2.000, %95 CI: 1.149-3.482) hastalık şiddeti için bağımsız bir öngördürücü olarak bulundu. Algılayıcı işletim eğrisinden gelen eğri değeri, pnömoni şiddetini belirlemek için 0.879 (p<0.001, % 95 CI: 0.784-0.943) idi. İPF, hastalığın şiddetini saptamak için %69.5?lik duyarlılık ve %92.4?lük özgüllük değerine sahipti. Sonuç: İPF, COVID-19 pnömonisinin şiddeti için bağımsız bir öngörücüdür. %İPF’nin değerlendirilmesi, hem COVID-19? lu yüksek riskli hastaları erken belirlemeye hem de hekimleri uyarmaya yardımcı olabilir.
  • Thumbnail Image
    PublicationOpen Access
    The role of obesity in predicting the clinical outcomes of COVID-19
    (Karger Publishers, 2021) Şahin, Serdar; Yağız Özgül, Yeliz; Yıldırım, Murat; İçli, Tevhide Betül; Polat Korkmaz, Özge; Durcan, Emre; Sulu, Cem; Börekçi, Şermin; Yazıcı, Tabak, Fehmi; Dikmen, Yalim; Özkaya, Hande Mefkure; Gönen, Mustafa Sait; Damcı, Taner; İlkova, Hasan; Yumuk, Volkan Demirhan; Çiçek, Ebru; Dereli, Dilek Yazıcı; Deyneli, Oğuzhan; Ergönül, Önder; Sezer, Havva; Somay, Kayra; Bekdemir, Bahar; Faculty Member; Faculty Member; Faculty Member; Teaching Faculty; School of Medicine; Koç University Hospital; 179659; 171914; 110398; N/A; N/A; N/A
    Introduction: the aim of this was to describe the predictors of mortality related to COVID-19 infection and to evaluate the association between overweight, obesity, and clinical outcomes of COVID-19. Methods: we included the patients >18 years of age, with at least one positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction. Patients were grouped according to body mass index values as normal weight <25 kg/m(2) (Group A), overweight from 25 to <30 kg/m(2) (Group B), Class I obesity 30 to <35 kg/m(2) (Group C), and >= 35 kg/m(2) (Group D). Mortality, clinical outcomes, laboratory parameters, and comorbidities were compared among 4 groups. Results: there was no significant difference among study groups in terms of mortality. Noninvasive mechanical ventilation requirement was higher in group B and D than group A, while it was higher in Group D than Group C (Group B vs. Group A [p = 0.017], Group D vs. Group A [p = 0.001], and Group D vs. Group C [p = 0.016]). Lung involvement was less common in Group A, and presence of hypoxia was more common in Group D (Group B vs. Group A [p = 0.025], Group D vs. Group A [p < 0.001], Group D vs. Group B [p = 0.006], and Group D vs. Group C [p = 0.014]). The hospitalization rate was lower in Group A than in the other groups; in addition, patients in Group D have the highest rate of hospitalization (Group B vs. Group A [p < 0.001], Group C vs. Group A [p < 0.001], Group D vs. Group A [p < 0.001], Group D vs. Group B [p < 0.001], and Group D vs. Group C [p = 0.010]). Conclusion: COVID-19 patients with overweight and obesity presented with more severe clinical findings. Health-care providers should take into account that people living with overweight and obesity are at higher risk for COVID-19 and its complications.